
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics is a strong and diversified medical company with a focus on innovative products and solutions in the blood and plasma industry. With stable revenue growth and plans for improvements in operating margins, the company has shown promising financial performance. While there are concerns about the decline in interventional technologies, the company's overall growth potential and solid reputation make it a solid investment option. Risk factors such as competition and fluctuations in procedure volumes are also important considerations.
Bears say
Haemonetics is facing challenges in the competitive blood center segment, reflected by the decline of 19.6% in reported revenue in the latest quarter. Despite increasing expectations for organic growth in this segment, there is still uncertainty surrounding the company's ability to compete effectively. This, combined with the fact that the plasma and hospital segments drive the majority of revenue, leads to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares